| Literature DB >> 32295297 |
Yasmine Lund-Ricard1, Patrick Cormier1, Julia Morales1, Agnès Boutet1.
Abstract
A major challenge in medical research resides in controlling the molecular processes of tissue regeneration, as organ and structure damage are central to several human diseases. A survey of the literature reveals that mTOR (mechanistic/mammalian target of rapamycin) is involved in a wide range of regeneration mechanisms in the animal kingdom. More particularly, cellular processes such as growth, proliferation, and differentiation are controlled by mTOR. In addition, autophagy, stem cell maintenance or the newly described intermediate quiescence state, Galert, imply upstream monitoring by the mTOR pathway. In this review, we report the role of mTOR signaling in reparative regenerations in different tissues and body parts (e.g., axon, skeletal muscle, liver, epithelia, appendages, kidney, and whole-body), and highlight how the mTOR kinase can be viewed as a therapeutic target to boost organ repair. Studies in this area have focused on modulating the mTOR pathway in various animal models to elucidate its contribution to regeneration. The diversity of metazoan species used to identify the implication of this pathway might then serve applied medicine (in better understanding what is required for efficient treatments in human diseases) but also evolutionary biology. Indeed, species-specific differences in mTOR modulation can contain the keys to appreciate why certain regeneration processes have been lost or conserved in the animal kingdom.Entities:
Keywords: appendage; autophagy; axon; differentiation; epidermis; human diseases; kidney; liver; mTOR pathway; muscle; proliferation; regeneration; stem cell; whole-body
Mesh:
Substances:
Year: 2020 PMID: 32295297 PMCID: PMC7216262 DOI: 10.3390/ijms21082718
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Glossary of key terms used in this review.
| Definition |
|---|
Figure 1A simplified mTOR (mechanistic/mammalian target of rapamycin) pathway with upstream signals, which activate or inhibit mTORC1 or mTORC2 activities. mTORC1 activity is sensitive to growth factors, energy levels, oxygen, amino acids, and stress while mTORC2 activity responds to growth factors only. Below, the main cellular processes, which are affected by mTOR activity. mTORC1 activity leads to cell growth, cell cycle progression with an increased phosphorylation of S6K1/2 (S6 kinase 1/2) and 4E-BP (4E binding protein). mTORC1 activity inhibits autophagy. mTORC2 activity controls cell survival, proliferation, and migration.
Figure 2This figure illustrates the ways in which activity from the mTOR signaling pathway contributes to appendage (a) or muscle regeneration (b,c): (a) Concerning appendage regeneration, the Wnt/β-catenin pathway and insulin-like growth factor (IGF-1) activate mTORC1. This activity leads to the wound covering, blastema formation and regenerative outgrowth of the appendage. (b) During muscle regeneration, mTORC1 activity is necessary for myofiber growth but not myogenesis. mTORC1 inhibition by rapamycin treatment inhibits regeneration whereas the leucine amino acid, insulin-like growth factor 1 or Akt activity contribute to mTORC1-mediated muscle regeneration. SPAR regulatory protein (small regulatory polypeptide of amino acid response) can inhibit mTORC1 activity and hinder muscle regeneration. (c) mTORC1 signaling is necessary for muscle regeneration in the injured limb and to induce a Galert state in the contralateral limb. The Galert cells enter the cell cycle more rapidly and show an increase in size compared to quiescent satellite cells.
Figure 3This figure illustrates how activity from the mTOR signaling pathway contributes to axon regeneration in the selected examples of retinal nerve damage (a) and spinal cord injury (b,c): (a) Concerning retinal nerve regeneration, mTOR activity enhances axon elongation and survival leading to functional regeneration. Signals that upregulate mTOR activity like PTEN inhibition, siRTP801, Pam3Cys (pro-inflammatory signal), CNTF (ciliary neurotrophic factor) or IGF-1 lead to axon recovery. TOR-independent axon recovery exists however as rapamycin-treated PTEN-deleted neurons and Pam3Cys untreated neurons still showed recovery. (b) For spinal cord injuries, mTORC1 activity in astrocytes hinders neuronal recovery with the formation of glial scars (gliosis). Growth factors like EGF (epidermal growth factor) can activate mTORC1. (c) On the contrary, mTORC1 signaling in hemisection spinal cord injuries promotes growth and functional regeneration.
Figure 4This figure illustrates the ways in which activity from the mTOR signaling pathway contributes to epidermis (a), gut (b) and liver regeneration (c): (a) mTORC1 activity is necessary for wound closure and can be enhanced by insulin/insulin-like growth factor signaling (IIS). S6K1/2 is a TOR target which helps wound closure. mTOR inhibitory signals like rapamycin or an overexpressed PRAS40 delay wound closure and promote autophagy. (b) For gut regeneration, mTORC1 activity is required for initial cell proliferation but chronic activation leads to intestinal stem cell exhaustion. (c) For liver regeneration, mTORC1 activity leads to cell cycle reentry and functional recovery. eIF4E (Eukaryotic Initiation Factor 4E) dependent translation is activated with mTORC1 activity and leads to Cyclin D expression. Cyclin D amplifies cell proliferation and leads to functional liver recovery.
Figure 5This figure illustrates the ways in which the mTOR signaling pathway contributes to bone (a) or kidney (b) regeneration. (a) mTOR activity (mTORC1 and mTORC2) is required for osteoblast and osteoclast differentiation. mTORC1 is activated by bone morphogenetic protein (BMP), insulin-like growth factor 1 (IGF-1) and Wnt signaling. mTORC1 inhibition promotes stem cell maintenance and autophagy while mTORC2 inhibition leads to cell fate change. (b) In the kidney, hypertrophic recovery depends on mTORC1 activity. mTOR activity has been correlated to stem cell depletion such as that mTOR inhibition (purple) might play a role in maintaining kidney progenitors.
Figure 6Whole-body regeneration (as explained for cnidarians and planarians) involves different phases of mTORC activity. mTORC inhibition and its induced autophagy are associated with a large increase in cellular ATP which could contribute to stem cell activation. Autophagy is also involved in the process of transdifferentiation, often preceded by dedifferentiation. In combination with mTORC1 inhibition, retinoic acid stimulation induces transdifferentiation. DAP-1 (Death-associated protein 1) inhibits autophagy in conditions of nutrient deprivation. Finally, mTORC activity is upregulated for the regrowth of the missing structure.
Summary of the implication of the mTOR pathway in different regenerative processes.
| Regenerative Process | Role of mTOR in Regeneration | Animal Model and References |
|---|---|---|
| Appendage | mTORC1 is required and mTOR genes are differentially expressed during regeneration. | Teleost [ |
| Muscle | mTORC1 controls an alert satellite cell state, is required for cell proliferation and differentiation and for myofiber growth. | Mouse [ |
| Axon | mTORC1 activity stimulates axon survival, growth and functional recovery after injury of the central nervous system. mTOR inhibition serves regeneration by inhibiting gliosis. | Mouse [ |
| Epidermis | mTORC1 activity activates cell proliferation and wound repair. | |
| Gut | mTOR activity is necessary for gut cell growth and proliferation but continued activation leads to stem cell exhaustion. | |
| Liver | mTOR activity is required for hepatocyte proliferation and leads to functional recovery for up to 70% partial hepactectomy. | Mouse [ |
| Bone | mTORC1 activity mediates osteoblast and osteoclast differentiation and stem cell maintenance. mTORC2 activity influences cell fate. | Mouse [ |
| Kidney | mTORC1 mediates hypertrophic response following kidney injuries. | Rat [ |
| Whole-body | mTOR genes are downregulated during pre-regenerative autophagy but activity is required for initial mitotic response and blastema formation. |